FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma
esmo - Evidence for efficacy is based on the results from the LITESPARK-022 study
AI Summary: Regulators have cleared the combination of belzutifan and pembrolizumab as adjuvant therapy for renal cell carcinoma at high risk of recurrence after nephrectomy. Clinical data showed improved disease‑free survival versus control, offering a new post‑surgery option intended to delay recurrence in patients with residual recurrence risk.
Related Stories
FDA greenlights datopotamab deruxtecan for metastatic TNBC / 29 days
FDA approves belzutifan (Welireg) plus pembrolizumab for adjuvant RCC / 5 wks
FDA clears first all-oral regimen for certain newly diagnosed AML patients / 7 wks
VOLGA Phase III shows survival benefit for bladder cancer neoadjuvant combo / 2 months
FDA clears Trodelvy alone and with Keytruda for first-line TNBC / 29 days
Datroway secures regulatory approvals in breast cancer across US and EU / 2 months
FDA clears first targeted therapy for ultra-rare NRG1-driven cholangiocarcinoma / 2 months
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Price Transparency, Cancer Screening, Digital Health, Cybersecurity and look for the RSS link.
StackHealth Time Machine